1. Home
  2. CRDL vs ALTS Comparison

CRDL vs ALTS Comparison

Compare CRDL & ALTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDL
  • ALTS
  • Stock Information
  • Founded
  • CRDL 2017
  • ALTS 1976
  • Country
  • CRDL Canada
  • ALTS United States
  • Employees
  • CRDL N/A
  • ALTS N/A
  • Industry
  • CRDL Biotechnology: Biological Products (No Diagnostic Substances)
  • ALTS
  • Sector
  • CRDL Health Care
  • ALTS
  • Exchange
  • CRDL Nasdaq
  • ALTS NYSE
  • Market Cap
  • CRDL 80.1M
  • ALTS 93.4M
  • IPO Year
  • CRDL N/A
  • ALTS N/A
  • Fundamental
  • Price
  • CRDL $1.15
  • ALTS $6.62
  • Analyst Decision
  • CRDL Strong Buy
  • ALTS
  • Analyst Count
  • CRDL 3
  • ALTS 0
  • Target Price
  • CRDL $9.00
  • ALTS N/A
  • AVG Volume (30 Days)
  • CRDL 150.5K
  • ALTS 157.2K
  • Earning Date
  • CRDL 05-20-2025
  • ALTS 05-23-2025
  • Dividend Yield
  • CRDL N/A
  • ALTS N/A
  • EPS Growth
  • CRDL N/A
  • ALTS N/A
  • EPS
  • CRDL N/A
  • ALTS N/A
  • Revenue
  • CRDL N/A
  • ALTS $12,532,000.00
  • Revenue This Year
  • CRDL N/A
  • ALTS N/A
  • Revenue Next Year
  • CRDL N/A
  • ALTS N/A
  • P/E Ratio
  • CRDL N/A
  • ALTS N/A
  • Revenue Growth
  • CRDL N/A
  • ALTS N/A
  • 52 Week Low
  • CRDL $0.77
  • ALTS $1.29
  • 52 Week High
  • CRDL $3.12
  • ALTS $7.75
  • Technical
  • Relative Strength Index (RSI)
  • CRDL 57.19
  • ALTS 64.93
  • Support Level
  • CRDL $1.02
  • ALTS $5.50
  • Resistance Level
  • CRDL $1.19
  • ALTS $6.28
  • Average True Range (ATR)
  • CRDL 0.07
  • ALTS 0.63
  • MACD
  • CRDL 0.01
  • ALTS 0.08
  • Stochastic Oscillator
  • CRDL 73.53
  • ALTS 71.58

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About ALTS ALT5 SIGMA CORPORATION

ALT5 Sigma Corp is a fintech company. The company operates in three operating segments: Fintech: provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, Biotechnology: Biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties; Corporate and Others: Corporate and Other segment consists of certain corporate general and administrative costs. Company has revenue from Fintech Segment.

Share on Social Networks: